Cencora, Inc. (COR)
| Market Cap | 56.43B |
| Revenue (ttm) | 316.65B |
| Net Income (ttm) | 1.90B |
| Shares Out | 193.88M |
| EPS (ttm) | 9.68 |
| PE Ratio | 30.08 |
| Forward PE | 17.03 |
| Dividend | $2.20 (0.76%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 1,263,378 |
| Open | 291.29 |
| Previous Close | 289.15 |
| Day's Range | 289.09 - 293.57 |
| 52-Week Range | 218.65 - 309.35 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 308.83 (+6.11%) |
| Earnings Date | Aug 6, 2025 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply ... [Read more]
Financial Performance
In 2024, Cencora's revenue was $293.96 billion, an increase of 12.12% compared to the previous year's $262.17 billion. Earnings were $1.51 billion, a decrease of -13.53%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for COR stock is "Buy." The 12-month stock price target is $308.83, which is an increase of 6.11% from the latest price.
News
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap
Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x for...
Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy
I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and...
Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript
Cencora, Inc. (NYSE:COR) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.
Cencora raises annual profit forecast on strong demand for specialty drugs
U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and bl...
Cencora Reports Fiscal 2025 Third Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On...
Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the openi...
Cencora Elects Lori J. Ryerkerk to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms. Ryerk...
Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs
Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can d...
Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings
Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S...
Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript
Cencora, Inc. (NYSE:COR) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - Preside...
Cencora Reports Fiscal 2025 Second Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion....
3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock
The S&P 500's three top performers in 2025 boast characteristics that could help them weather a further sell off.
Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening...
Cencora: Higher Potential Returns After Reduced Walgreens Stake
Cencora offers steady revenue growth from pharmaceutical distribution, benefiting from rising healthcare demand and an aging population. The company has a strong economic moat, low leverage, BBB+ cred...
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...
Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) has agreed to the early settlement of certain prepaid variable share forward transactions it had previously entered into ...
Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation...
Cencora (COR) Q1 2025 Earnings Call Transcript
Cencora Inc. (NYSE:COR) Q1 2025 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Robert Mauch - President, Chief Executive Officer James Cleary - Executive Vice President, Ch...
Cencora raises 2025 profit forecast on specialty drug demand
Drug distributor Cencora raised its fiscal 2025 profit forecast on Wednesday, driven by robust demand for expensive specialty medicines.
Cencora Reports Fiscal 2025 First Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 first quarter ended December 31, 2024, revenue increased 12.8 percent year-over-year to $81.5 billio...
Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategi...
Using SA's Stock Screener: Sell 6 Overvalued Blue Chips, With Stagnating Growth
Seeking Alpha's Quant Valuation and Growth Grades identify 6 blue-chip stocks with extremely high valuations matched against limited operating growth potential. Costco, Cencora, West Pharmaceutical Se...
Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the ope...
Cencora raises annual profit forecast
Drug distributor Cencora raised its annual adjusted profit forecast on Thursday.